US FDA delays verdict on Pfizer/BMS stroke prevention drug
This article was originally published in Scrip
Executive Summary
The US FDA has delayed by three months its decision on the new drug application (NDA) for Bristol-Myers Squibb's and Pfizer's experimental anticoagulant Eliquis (apixaban) as a therapy to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.